La Jolla, CALIFORNIA2 Active Studies

Spinal Muscular Atrophy Clinical Trials in La Jolla, CALIFORNIA

Find 2 actively recruiting spinal muscular atrophy clinical trials in La Jolla, CALIFORNIA. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
435
Enrolling

Recruiting Spinal Muscular Atrophy Studies in La Jolla

About Spinal Muscular Atrophy Clinical Trials in La Jolla

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder that causes loss of motor neurons, leading to progressive muscle weakness and atrophy. It is the leading genetic cause of infant death. Revolutionary gene therapies and SMN-enhancing drugs have transformed treatment.

There are currently 2 spinal muscular atrophy clinical trials recruiting participants in La Jolla, CALIFORNIA. These studies are seeking a combined 435 participants. Research is being sponsored by Janssen Research & Development, LLC, National Cancer Institute (NCI). Clinical trial participation is free and participants receive study-related medical care at no cost.

Spinal Muscular Atrophy Clinical Trials in La Jolla — FAQ

Are there spinal muscular atrophy clinical trials in La Jolla?

Yes, there are 2 spinal muscular atrophy clinical trials currently recruiting in La Jolla, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in La Jolla?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the La Jolla research site will contact you about next steps.

Are clinical trials in La Jolla free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many La Jolla studies also compensate for your time and travel.

What spinal muscular atrophy treatments are being tested?

The 2 active trials in La Jolla are testing new therapies including novel drugs, biologics, and treatment approaches for spinal muscular atrophy.

Data updated March 2, 2026 from ClinicalTrials.gov